# Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

> **NCT04333004** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xiaorong Dong** · enrollment: 40 (estimated)

## Conditions studied

- Gut Microbiota
- NSCLC
- Pembrolizumab
- Chemotherapy

## Interventions

- **DRUG:** Pembrolizumab Combined With Chemotherapy

## Key facts

- **NCT ID:** NCT04333004
- **Lead sponsor:** Xiaorong Dong
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04
- **Primary completion:** 2021-04
- **Final completion:** 2022-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333004, "Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04333004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*